Ironwood Pharmaceuticals (IRWD) expects adjusted EBITDA in FY25 to exceed $135M, with $200M+ in cash by end of Q4. FDA meeting confirms Phase 3 trial design for apraglutide in short bowel syndrome. Trial set to start in H1 2026. Company on track to meet LINZESS sales and revenue targets for 2025. CEO optimistic about financial progress.

Read more at Yahoo Finance: Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M